Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 29 of 29

TitleReference numberPublishedLast updated
Bimekizumab for treating active psoriatic arthritisTA916
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Upadacitinib for treating moderate rheumatoid arthritisTA744
Tofacitinib for treating juvenile idiopathic arthritisTA735
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Upadacitinib for treating severe rheumatoid arthritisTA665
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Sarilumab for moderate to severe rheumatoid arthritisTA485
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Baricitinib for moderate to severe rheumatoid arthritisTA466
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Ustekinumab for treating active psoriatic arthritisTA340
Apremilast for treating active psoriatic arthritisTA433
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hipTA304
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)TA302
Tocilizumab for the treatment of rheumatoid arthritisTA247
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Golimumab for the treatment of psoriatic arthritisTA220
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritisTA199

Results per page

  1. 10
  2. 25
  3. 50
  4. All